Search

Your search keyword '"Agema, W.R.P."' showing total 6 results
Start Over Author "Agema, W.R.P."
6 results on '"Agema, W.R.P."'

1. Guidelines for the management of myocardial infarction/injury with non-obstructive coronary arteries (MINOCA): a position paper from the Dutch ACS working group

Author

Pustjens, T.F.S., Appelman, Y., Damman, P., Berg, J.M. ten, Jukema, J.W., Winter, R.J. de, Agema, W.R.P., Wielen, M.L. van der, Arslan, F., Rasoul, S., Hof, A.W.J. van ’t, Pustjens, T.F.S., Appelman, Y., Damman, P., Berg, J.M. ten, Jukema, J.W., Winter, R.J. de, Agema, W.R.P., Wielen, M.L. van der, Arslan, F., Rasoul, S., and Hof, A.W.J. van ’t

Abstract

Contains fulltext : 220920.pdf (Publisher’s version ) (Open Access), Patients with myocardial infarction and non-obstructive coronary arteries (MINOCA), defined as angiographic stenosis <50%, represent a conundrum given the many potential underlying aetiologies. Possible causes of MINOCA can be subdivided into coronary, myocardial and non-cardiac disorders. MINOCA is found in up to 14% of patients presenting with an acute coronary syndrome. Clinical outcomes including mortality, and functional and psychosocial status, are comparable to those of patients with myocardial infarction and obstructive coronary arteries. However, many uncertainties remain regarding the definition, clinical features and management of these patients. This position paper of the Dutch ACS working group of the Netherlands Society of Cardiology aims to stress the importance of considering MINOCA as a dynamic working diagnosis and to guide the clinician in the management of patients with MINOCA by proposing a clinical diagnostic algorithm.

Published
2020

3. Tumor necrosis factor-α plays an important role in restenosis development

Author

Monraats, P.S., Pires, N.M.M., Schepers, A., Agema, W.R.P., Boesten, L.S.M., Vries, M.R. de, Zwinderman, A.H., Maat, M.P.M. de, Doevendans, P.A.F.M., Winter, R.J. de, Tio, R.A., Waltenberger, J., Hart, L.M. 't, Frants, R.R., Quax, P.H.A., Vlijmen, B.J.M. van, Havekes, L.M., Laarse, A. van der, Wall, E.E. van der, Jukema, J.W., and TNO Kwaliteit van Leven

Subjects
Male, Biomedical Research, Heredity, Apolipoprotein E3, Coronary Disease, Constriction, Pathologic, Clinical practice, Coronary Angiography, Linkage Disequilibrium, Percutaneous coronary intervention, Mice, Ischemia, Risk Factors, Haplotype, TNFα, Odds Ratio, Biology Health, Transgenic mice, Angioplasty, Transluminal, Percutaneous Coronary, Risk assessment, Mice, Knockout, Reverse Transcriptase Polymerase Chain Reaction, Messenger RNA, Angiography, Middle Aged, Thalidomide, Up-Regulation, Femoral Artery, Gene Expression Regulation, Neoplastic, Treatment Outcome, Screening, Regression Analysis, Female, Adult, Genotype, Drug delivery system, Mice, Transgenic, Angina Pectoris, Coronary Restenosis, Knockout mouse, Animals, Humans, Animalia, Mus musculus, Animal model, Genetic Predisposition to Disease, Animal experiment, RNA, Messenger, Alleles, Aged, Inflammation, Genetic polymorphism, Polymorphism, Genetic, Restenosis, Tumor necrosis factor alpha, Tumor Necrosis Factor-alpha, Nonhuman, Disease Models, Animal, Haplotypes, Multivariate Analysis, Disease marker
Abstract

Genetic factors appear to be important in the restenotic process after percutaneous coronary intervention (PCI), as well as in inflammation, a pivotal factor in restenosis. TNFα, a key regulator of inflammatory responses, may exert critical influence on the development of restenosis after PCI. The GENetic DEterminants of Restenosis (GENDER) project included 3104 patients who underwent a successful PCI. Systematic genotyping for six polymorphisms in the TNFα gene was performed. The role of TNFα in restenosis was also assessed in ApoE*3-Leiden mice, TNFα knockout mice, and by local delivery of a TNFα biosynthesis inhibitor, thalidomide. The -238G-1031T haplotype of the TNFα gene increased clinical and angiographic risk of restenosis (P=0.02 and P=0.002, respectively). In a mouse model of reactive stenosis, arterial TNFα mRNA was significantly time-dependently up-regulated. Mice lacking TNFα or treated locally with thalidomide showed a reduction in reactive stenosis (P=0.01 and P=0.005, respectively). Clinical and preclinical data indicate that TNFα plays an important role in restenosis. Therefore, TNFα genotype may be used as a risk marker for restenosis and may contribute to individual patient screening prior to PCI in clinical practice. Inhibition of TNFα may be an anti-restenotic target strategy. ©FASEB. Chemicals / CAS: thalidomide, 50-35-1; RNA, Messenger; Thalidomide, 50-35-1; Tumor Necrosis Factor-alpha

Published
2005

4. Current PTCA practice and clinical outcomes in the Netherlands: The real world in the pre-drug-eluting stent era

Author

Agema, W.R.P., Monraats, P.S., Zwinderman, A.H., Winter, R.J. de, Tio, R.A., Doevendans, P.A.F.M., Waltenberger, J., Maat, M.P.M. de, Frants, R.R., Atsma, D.E., Laarse, A. van der, Wall, E.E. van der, Jukema, J.W., and Gaubius Instituut TNO

Subjects
Male, Biomedical Research, hypertension, ticlopidine, heart disease, Coronary Restenosis, restenosis, coronary artery bypass graft, Risk Factors, Myocardial Revascularization, follow up, Humans, heart death, Angioplasty, Transluminal, Percutaneous Coronary, Prospective Studies, Percutaneous transluminal coronary angioplasty, Biology, Netherlands, Drug Implants, clopidogrel, adult, practice guideline, fibrinogen receptor antagonist, clinical trial, Professional Practice, acetylsalicylic acid, Middle Aged, stable angina pectoris, interventional cardiovascular procedure, major clinical study, acute heart infarction, aged, multicenter study, Treatment Outcome, risk factor, peripheral vascular disease, diabetes mellitus, revascularization, Female, Stents, drug eluting stent, transluminal coronary angioplasty, Follow-Up Studies
Abstract

Aims To document the practice of interventional cardiology and the clinical restenosis rate, as well as the risk factors for clinical restenosis in an unselected population of patients in daily practice and to provide a perspective for the need of new devices such as drug-eluting stents. Methods and results A total of 3177 consecutive patients, who underwent successful percutaneous transluminal coronary angioplasty (PTCA) in the Netherlands, were included. Patients with acute myocardial infarction were excluded. The pre-defined end-point of clinical restenosis was defined as cardiac death, myocardial infarction and revascularisation of the target vessel. Follow-up (9.6 months, IQR 3.9) was complete in 3146 (99.3%) patients with a mean age of 62.1±10.7 years. Of them 896 (28.5%) were female, 459 (14.6%) had diabetes and 1459 (46.4%) had multi-vessel disease. Most patients (2105, 66.9%) were treated for stable angina. Of all patients, 819 (26.0%) were treated for multiple lesions, 2340 (74.4%) underwent stenting and 820 (26.1%) received glycoprotein IIb/IIIa inhibitors. All stented patients received life-long aspirin and ticlopidin/clopidogrel during at least 1 month after the procedure. Target vessel revascularisation during follow-up by either coronary artery by-pass grafting (CABG) or PTCA was necessary in 304 patients (9.7%). Thirty-three (1.1%) patients died of cardiac disease and 22 (0.7%) patients suffered from myocardial infarction (MI) attributable to the originally treated vessel. Overall, the need for revascularisation, or the incidence of cardiac death or MI occurred in 346 patients (11.0%), at 9 and 12 months these event-rates were 10.2% and 12.0%, respectively. Diabetes, hypertension, peripheral vessel disease, multi-vessel disease and treatment of type C lesions prevailed as independent risk factors for clinical restenosis. Longer stents and smaller minimal stent diameter were risk factors for in-stent stenosis. Conclusion In this unselected series of consecutive patients treated for stable and unstable angina in everyday clinical practice in the pre-drug-eluting stent era, clinical restenosis after 9 and 12 months follow-up of the patients occurred in 10.2% and 12.0%, respectively. The risk varies from 8.3% to 17.6% depending on the number of risk factors. A proper selection of patients that benefit from new devices warranted, since the vast majority are well-treated with standard techniques and proper assignment of expensive new devices is obviously of importance for overall health care. © 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved. Chemicals / CAS: acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; clopidogrel, 113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8; ticlopidine, 53885-35-1, 55142-85-3; Drug Implants

Published
2004

5. Current PTCA practice and clinical outcomes in the Netherlands: the real world in the pre-drug-eluting stent era: the real world in the pre-drug-eluting stent era

Author

Agema, W.R.P., Monraats, P.S., Zwinderman, A.H, de Winter, R.J., Tio, R.A., Doevendans, P.A.F.M., Waltenberger, J., De Maat, M.P.M., Frants, R.R., Atsma, D.E., Van der Laarse, A., van der Wall, E.E., Jukema, J.W., and Rijksuniversiteit Groningen

Subjects
restenosis, PERCUTANEOUS CORONARY INTERVENTIONS, BALLOON ANGIOPLASTY, percutaneous transluminal, ARTERY DISEASE, PLACEMENT, risk factors, REVASCULARIZATION, coronary angioplasty
Published
2004

6. Aortic valve regurgitation due to cusp aneurysm: a case report.

Author

Scholte, A.J.H.A, Agema, W.R.P, Poldermans, D, Somer, S.T, Holman, E.R, van der Wall, E.E, and Bax, J.J

Subjects
AORTIC valve insufficiency, TWO-dimensional echocardiography, AORTIC valve transplantation, AORTITIS
Abstract

Two-dimensional echocardiography is a valuable tool in visualizing and monitoring aortic valve and root abnormalities. We present a rare case of a patient with massive aortic regurgitation due to cusp aneurysm, which was accurately diagnosed by echocardiography and treated by valve replacement. A complicated course with recurrent aneurysms of the aortic wall after aortic valve replacement was remarkable in this case. Although different possible etiologies could not be determined, endocarditis and/or aortitis may be the most likely explanation of the complicated and finally fatal course of this patient. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results